Extraneural Metastasis of Ependymoma in the Cauda Equina

Takahito Fujimori1  Motoki Iwasaki1  Yukitaka Nagamoto1  Masafumi Kashii1  Hironobu Sakaura2  Hideki Yoshikawa1

1 Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
2 Department of Orthopedic Surgery, Kansai Rosai Hospital, Hyogo, Japan

Abstract

We report a rare case of extraneural metastasis of spinal ependymoma that developed over a very long period. A 28-year-old man underwent surgery for ependymoma in the cauda equina. After he experienced three local recurrences and had undergone five operations, a lung metastasis occurred 46 years after the first operation. Although the tumor did not show the typical morphological malignancy, the maximum standard uptake value obtained by positron-emission tomography and the antigen Ki-67 labeling index demonstrated the tumor’s active proliferative ability. One year after the last operation, the patient died of respiratory failure due to progressing lung metastases. The malignant behavior of spinal ependymomas is demonstrated in a case with long-term follow-up.

Keywords
► ependymoma
► extraneural
► metastasis
► cauda equina

Case Report

History and Examination

A 28-year-old Asian man who reported low back pain underwent resection of a tumor of the cauda equina at the L4–5 level in 1963 (his first surgery). The pathological diagnosis was ependymoma. He remained free of symptoms for 20 years. At age 48 years in 1984, he underwent resection for recurrence of the tumor in the retroperitoneal space (his second surgery). He had no signs of recurrence for 13 years. Then at age 61 years, he had low back pain due to tumor recurrence. He underwent tumor resection, done using an anteroposterior approach (his third surgery); however, the resection was incomplete. At the age of 62 in 1998, he underwent total resection, attempted from a posterior approach (his fourth surgery) with arterial embolization. After the surgery, the patient underwent radiation therapy (45 Gy). His right leg was paralyzed as a complication of arterial embolization. The patient then remained free of symptoms for 10 years.

At the age of 73 in 2009, he was referred to our hospital for the first time, with moderate low back pain and intolerable left leg pain that had continued for 1 year. He was non-ambulatory because of loss of muscle and leg pain and had normal function of bladder and bowel. His neurological symptom suggested he suffered from left L5 radiculopathy. Plain radiographs and computed tomography showed scalloping of the lumbar spine with marginal sclerosis (► Fig. 1A). Magnetic resonance imaging revealed severe canal stenosis at

© 2013 Georg Thieme Verlag KG
Stuttgart · New York
DOI http://dx.doi.org/10.1055/s-0032-1329888.
ISSN 2192-5682.
the L4–5 level due to tumor expansion (►Figs. 1B, C). Preoperative plain chest radiographs depicted a coin-size lesion on his right lung, showing metastases of the tumors (►Fig. 2). Findings for various tumor makers were negative. A whole-body computed tomography scan detected no primary tumor other than one in the lumbar spine. We identified these lesions as metastases of ependymoma. Because the patient’s leg pain could not be controlled even with narcotic analgesics, we performed palliative decompression surgery.

**Surgical Procedure**

The posterior approach was used. During surgery, the cysts in the paravertebral muscle were found to be suffused with serous liquid and were resected in a piecemeal fashion. After exposing the left facet at L4–5, the residual left inferior articular process of L4 was resected. We curetted the tumors behind the dura mater with the use of a Cavitron Ultrasonic Surgical Aspirator (Cooper Medical, Santa Clara, CA) and identified the L5 nerve root. A soft brown tumor in the extradural space had compressed the L5 nerve root from the ventral side. An intralesional excision of the tumor was performed without adhesion.

**Pathological Findings**

Tissue sections obtained before 1984 were not acquired for review. The tumor resected in 1998 had proliferation of round cells, forming a perivascular pseudorosette (►Fig. 3A). Most of the tumor resected in 2009 had a morphologically identical pattern to that of the 1998 specimen. However, the pseudorosette pattern was more irregular in the 2009 tumor (►Fig. 3B). Immunohistochemistry produced positive findings for glial fibrillary acid protein (►Fig. 3C) and negative findings for epithelial membrane antigen. The histological and immunohistochemical findings led to the diagnosis of recurrent ependymoma. The Ki-67 labeling index for the 2009 tumor and the 1998 tumor was ~3% (►Fig. 3D). However, there was a limited area in the 2009 tumor with higher cell density than other areas. Some cellular pleomorphism, necrosis, and mitosis was present (►Fig. 3E), and the Ki-67 labeling index of the area was >15% (►Fig. 3F).

**Postoperative Course**

After surgery, muscle weakness and pain due to L5 radiculopathy was improved. Although low back pain remained, he became ambulatory with a cane. There were no complications.

---

**Figure 1** (A) Lateral radiographs of the lumbar spine showing scalloped vertebrae. (B) Sagittal T2-weighted magnetic resonance image showing the high signal intensity of cystic fluid in paravertebral muscle (small white arrow) and the low intensity of the tumor mass (large black arrow). The L5 vertebra was invaded by the tumor. (C) Axial T1-weighted contrast-enhanced image showing the isometric to high intensity of multiple tumors (arrows).

**Figure 2** Preoperative anteroposterior chest radiograph showing a coin-size lesion in the right lung field (arrow).
from the surgery. One month after surgery, fluorodeoxyglucose positron-emission tomography was performed for general examination. Pathological uptake was recognizable in the lumbar spine, a lung nodule, the ilium, and abdominal lymph nodes. The maximum standard uptake value ($SUV_{max}$) was 7.4 in the lumbar spine, 5.2 in a lung nodule, 4.0 in the ilium, and 3.8 in abdominal lymph nodes (►Fig. 4). Six months after surgery, there was extensive pulmonary metastasis (►Fig. 5) and bilateral leg swelling. Abdominal computed tomography revealed that the bilateral common iliac vein was occluded by deep vein thrombosis or tumor embolism. Although an inferior vena cava filter was placed to prevent pulmonary embolism, the patient was bedridden with deep vein thrombosis. One year after surgery, the patient died of respiratory failure at the age of 74, 46 years after the first surgery. Permission to perform an autopsy was denied by the patient’s family for religious reasons.

**Discussion**

Metastases of intradural ependymomas to other organs are rare events. To the best of our knowledge, only 10 cases of intradural ependymomas metastasizing outside the central nervous system (CNS) have been reported since 1955 (►Table 1).1–10

The common characteristics in cases of metastases are young age at onset, a long survival period, and multiple operations.1–3,6 Interestingly, in all 11 cases, the tumors originated in the cauda equina; there were no cases of intramedullary ependymoma with metastasis to other organs. It
was speculated that the reason for this was either that patients with intramedullary ependymomas have a short survival period or that multiple reoperations are difficult at this level. Mork and Loken reported that the 10-year survival rate for patients with ependymoma of the cauda equina was 94%, whereas the rate for patients with intramedullary ependymoma was only 55%. However, once the metastasis appeared, the prognosis for ependymoma of the cauda equina was very poor and therapeutic options were limited. The mean survival for five patients after metastasis was only 1.7 years (Table 1). Additionally, aggressive local invasion occurred at the time that the metastasis was noted. However, pathologically, few studies found cellular pleomorphism or mitosis, even after metastasis occurred. The relationship between histological type and metastatic potential has not been determined. In the same way, the most recent tumor in our patient also did not have a typical malignant morphology, such as mitosis or necrosis. However, some of our findings suggested a strong cell proliferative ability. A portion of our patient’s tumor had a high Ki-67 labeling index of 15%. Suri et al reported that the Ki-67 labeling index of CNS tumors was 0 to 2.4% for grade 1, 1.5 to 3.6% for grade 2, and 9.5 to 34% for grade 3. In a case of metastatic myxopapillary ependymoma, Rickert et al reported that the KI67 labeling index was 3.1% for the initial tumor and 14.2% for the recurrent tumor. These findings suggest the possibility of anaplastic-like change in recurrent ependymal tumors. Findings on positron-emission tomography also suggested a high activity level in our patient’s tumor. Even considering surgical invasion, the SUV_max of 7.4 for the lumbar spine and 5.2 for lung metastases in our patient was comparatively high. Kosaka et al reported that the mean SUV_max of malignant gliomas (grade 3 or 4) is 11.6 ± 3.7 and of metastatic brain tumors is 7.8 ± 2.7. Wilmshurst et al reported that the SUV_max of low-grade spinal cord tumors (grade 1 or 2) ranges from 1.0 to 5.2. The most likely pathway of extraneural metastasis of ependymal tumors is thought to be the bloodstream and/or the lymphatic system. However, in all reported cases of metastatic ependymomas there was a history of previous operations; the surgical manipulation itself had the possibility to produce distant metastases. In this sense, the characteristics of recurrent ependymomas in the extradural space rather resemble those of primary extradural ependymomas. It has been reported that patients with extradural ependymomas have a poor prognosis because they are at high risk for tumor metastasis to other organs instead of dissemination within the CNS. Because of the rarity of ependymomas, there have been no randomized, controlled studies of the effectiveness of adjuvant therapies in recurrence or metastasis of ependymomas. Most reports have supported some efficacy of radiation in preventing recurrence. Except in myxopapillary ependymomas in which total resection is confirmed by magnetic resonance imaging, the benefit of postoperative
Table 1  Studies Reporting Metastases of Ependymomas Outside the Central Nervous System

| Author and Year          | Age (y)/Sex | Origin/Histology | No. of Operations | No. of Radiotherapy Treatments/Total Dose (Gy) | No. of Chemotherapy Treatments | Total Survival (y) | Survival After Metastasis (y) | Metastases                                                                 |
|-------------------------|-------------|------------------|-------------------|-----------------------------------------------|--------------------------------|--------------------|-------------------------------|----------------------------------------------------------------------------|
| Weiss 1955<sup>9</sup>  | 22/M        | CE/ME            | 5                 | 2/42.4                                        | 10                             |                     |                               | Lung, liver, hilar lymph node, mediastinum, IVC, pleura, chest wall, diaphragm, pelvis |
| Sharma 1956<sup>7</sup> | 29/M        | CE/ME            | 3                 | 1                                             | 4                              |                     |                               | Lung, liver, mediastinum, pleura, chest wall, diaphragm                     |
| Patterson et al 1961<sup>4</sup> | 28/F   | CE/E             | 3                 | 2                                             | 17                             | 0                  |                               | Lung, liver, para-aortic lymph node, liver, mediastinum, IVC, pleura       |
| Rubinstein and Logan 1970<sup>6</sup> | 17/F | CE/E             | 3                 | 6/91.5                                        | 29                             |                     |                               | Lung, aortic lymph node, pleura, pelvis, rib                               |
| Wight et al 1973<sup>10</sup> | 20/M      | CE/ME            | 0                 | 2/NR                                          | 40                             | 3                  |                               | Para-aortic lymph node, pleura, pelvis, rib, humerus                      |
| Mavroudis et al 1977<sup>2</sup> | 7/M      | CE/E             | 5                 | 2/NR                                          | 8                              | 30                 |                               | Lung                                                                        |
| Morris et al 1983<sup>3</sup> | 10/F      | CE conus/E       | 3                 | 1/50                                          | 3                              | 12                 | 1                             | Lung, inguinal lymph node                                                  |
| Graf et al 1999<sup>1</sup> | 15/M      | CE conus/ME      | 1                 | 1/30                                          | 3                              | 40                 | 4                             | Lung, liver, abdominal and mediastinal lymph node, pleura, chest wall      |
| Rickert et al 1999<sup>5</sup> | 55/F      | CE/ME            | 3                 |                                               | 12                             |                     |                               | Lung                                                                        |
| Vega-Orozco et al 2011<sup>8</sup> | 22/M      | CE/ME            | 2                 | 1                                             | 16                             |                     |                               | Inguinal lymph node                                                        |
| Fujimori et al 2012 (this study) | 28/M | CE/E             | 5                 | 1/45                                          | 46                             | 0.5                |                               | Lung, abdominal lymph node, IVC, pelvis                                   |
| Mean                    | 28          |                  | 3.2               |                                               | 23                             | 1.7                |                               |                                                                            |

CE, cauda equina; E, ependymoma; F, female; IVC, inferior vena cava; M, male; ME, myxopapillary ependymoma; NR, not reported.
radiation outweighs the risk of adverse effects. However, the effectiveness of chemotherapy is less clear. Although several protocols have been attempted, few reports have shown that they are effective. Thus, there are few therapeutic options for metastasis.

Although most spinal ependymomas correspond to grade 1 or grade 2 tumors, the clinical course is not always good. Armstrong et al reported that nearly 40% of patients were unable to work from the time of diagnosis and had significant symptoms, such as pain, weakness, cognitive changes, and sexual dysfunction. Nakamura et al advocated treating spinal ependymomas as clinically malignant tumors. Local recurrence, CNS dissemination, and even metastasis can occur in the long term. Careful operation and long-term follow-up is recommended for patients with spinal ependymomas.

Acknowledgments
The authors thank Tadashi Watake, radiologist, for measuring SUV_{max} and Hideyuki Arita, neurosurgeon, and Hirostugu Oshima, pathologist, for advice on pathology findings. Katharine O’Moore-Klopf, ELS (East Setauket, NY), provided professional English-language editing of this article.

Disclosures
Takahito Fujimori, Research Support: AO spine research grant; a grant-in-aid for Scientific Research C (KAKENHI: 22591632) from the Ministry of Education, Culture, Sports and Technology, Japan
Motoki Iwasaki, Research Support: AO spine research grant; a grant-in-aid for Scientific Research C (KAKENHI: 22591632) from the Ministry of Education, Culture, Sports and Technology, Japan
Yukitaka Nagamoto, Research Support: AO spine research grant; a grant-in-aid for Scientific Research C (KAKENHI: 22591632) from the Ministry of Education, Culture, Sports and Technology, Japan
Masafumi Kashii, Research Support: AO spine research grant; a grant-in-aid for Scientific Research C (KAKENHI: 22591632) from the Ministry of Education, Culture, Sports and Technology, Japan
Hironobu Sakaura, Research Support: AO spine research grant; a grant-in-aid for Scientific Research C (KAKENHI: 22591632) from the Ministry of Education, Culture, Sports and Technology, Japan
Hideki Yoshikawa, Research Support: AO spine research grant; a grant-in-aid for Scientific Research C (KAKENHI: 22591632) from the Ministry of Education, Culture, Sports and Technology, Japan

References
1. Graf M, Blaeker H, Otto HF. Extranuclear metastasizing ependymoma of the spinal cord. Pathol Oncol Res 1999;5:56–60
2. Mavroudis C, Townsend JJ, Wilson CB. A metastasizing ependymoma of the cauda equina. Case report. J Neurosurg 1977;47:771–775
3. Morris DM, Steinert HR, Wiernik PH. Ineffectiveness of chemotherapy in patients with metastatic ependymoma of the cauda equina. J Surg Oncol 1983;22:33–36
4. Patterson RH Jr, Campbell WC Jr, Parsons H. Ependymoma of the cauda equina with multiple vesicular metastases. Report of a case. J Neurosurg 1961;18:145–150
5. Rickert CH, Kedziora O, Guillotta F. Ependymoma of the cauda equina. Acta Neurochir (Wien) 1999;141:781–782
6. Rubinstein LJ, Logan WJ. Extranuclear metastases in ependymoma of the cauda equina. J Neurol Neurosurg Psychiatry 1970;33:763–770
7. Sharma K. A metastasizing ependymoma of the cauda equina. Indian J Med Sci 1956;10:639–641
8. Vega-Orozco R, Rembao-Bojórquez D, Salmerón-Mercado M, García-Marquez A, Tena-Suck M. Inguinal lymph nodal metastasis of myxopapillary ependymoma confirmed by fine-needle aspiration cytology, biopsy, and immunohistochemistry: case report. Diagn Cytopathol 2011;39:689–693
9. Weiss L. A metastasizing ependymoma of the cauda equina. Cancer 1955;8:161–171
10. Wight DG, Holley KJ, Finbow JA. Metastasizing ependymoma of the cauda equina. J Clin Pathol 1973;26:929–935
11. Mork SJ, Loken AC. Ependymoma: a follow-up study of 101 cases. Cancer 1977;40:907–915
12. Suri VS, tatlee M, Singh D, et al. Histological spectrum of ependymomas and correlation of P53 and Ki-67 expression with ependymoma grade and subtype. Indian J Cancer 2004;41:66–71
13. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47–54
14. Prayson RA. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Am J Clin Pathol 1998;110:629–634
15. Rezai AR, Woo HH, Lee M, Cohen H, Zagzag D, Epstein FJ. Disseminated ependymomas of the central nervous system. J Neurosurg 1996;85:618–624
16. Schröder R, Ploner C, Ernestus RI. The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index. Neurol Rev 1993;16:145–150
17. Laufer I, Lis E, Pisinski L, Akhurst T, Blisky MH. The accuracy of [(18)F]fluoro-deoxyglucose positron emission tomography as confirmed by biopsy in the diagnosis of spine metastases in a cancer population. Neurosurgery 2009;64:107–113; discussion 113–114
18. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol 2008;190:W365–W369
19. Wilmshurst JM, Barrington SF, Pritchard D, et al. Positron emission tomography in imaging spinal cord tumors. J Child Neurol 2000;15:465–472
20. Hulbani S, Goodman PA. Glioblastoma multiforme with extraneural metastases in the absence of previous surgery. Cancer 1976;37:1577–1583
21. Bardales RH, Porter MC, Sawyer JR, Mrak RE, Stanley MW. Metastatic myxopapillary ependymoma: report of a case with fine-needle aspiration findings. Diagn Cytopathol 1994;10:47–53
22. Morantz RA, Kepes JJ, Batnitzky S, Masterson BJ. Extrapinal ependymomas. Report of three cases. J Neurosurg 1979;51:383–391
23. Helwig EB, Stern JB. Subcutaneous sacrococcygeal myxopapillary ependymoma. A clinicopathologic study of 32 cases. Am J Clin Pathol 1984;81:156–161
24. Kindblom LG, Lodding P, Hagmar B, Stenman G. Metastasizing myxopapillary ependymoma of the sacrococcygeal region. A clinicopathologic, light- and electronmicroscopic, immunohistochemical, tissue culture, and cytogenetic analysis of a case. Acta Pathol Microbiol Immunol Scand [A] 1986;94:79–90
25 Kramer GW, Rutten E, Sloof J. Subcutaneous sacrococcygeal ependymoma with inguinal lymph node metastasis. Case report. J Neurosurg 1988;68:474–477
26 Miralbell R, Louis DN, O’Keeffe D, Rosenberg AE, Suit HD. Metastatic ependymoma of the sacrum. Cancer 1990;65:2353–2355
27 Chamberlain MC. Salvage chemotherapy for recurrent spinal cord ependymoma. Cancer 2002;95:997–1002
28 Celli P, Cervoni L, Cantore G. Ependymoma of the filum terminale: treatment and prognostic factors in a series of 28 cases. Acta Neurochir (Wien) 1993;124:99–103
29 Fassett DR, Schmidt MH. Lumbosacral ependymomas: a review of the management of intradural and extradural tumors. Neurosurg Focus 2003;15:E13
30 Nakamura M, Ishii K, Watanabe K, et al. Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine 2009;34:E756–E760
31 Waldron JN, Laperriere NJ, Jaakkimainen L, et al. Spinal cord ependymomas: a retrospective analysis of 59 cases. Int J Radiat Oncol Biol Phys 1993;27:223–229
32 Sonneland PR, Scheithauer BW, Onofrio BM. Myxopapillary ependymoma. A clinicopathologic and immunocytochemical study of 77 cases. Cancer 1985;56:883–893
33 Moynihan TJ. Ependymal tumors. Curr Treat Options Oncol 2003;4:517–523
34 Armstrong TS, Vera-Bolanos E, Gilbert MR. Clinical course of adult patients with ependymoma: results of the Adult Ependymoma Outcomes Project. Cancer 2011;117:5133–5141